CELSET Launches SOLTOX Botulinum Toxin Type A Brand Internationally
Image
SEOUL – October 29, 2026 -- Korean biotechnology company CELSET INC. has launched SOLTOX, a botulinum toxin type A brand, in 100 Unit and 200 Unit formulations for international medical aesthetics markets.
SOLTOX combines a 900 kDa complex with a freeze-dried dosage form
The product is built on three technical characteristics: a 900 kDa toxin complex, a lyophilized powder format and an advanced purification process. The powder is reconstituted before administration by qualified medical professionals, in line with product labeling and local requirements.
CELSET states that the 900 kDa figure describes the molecular size of the toxin protein complex, including associated proteins. The company says it does not establish a claim of superior clinical duration or efficacy.